NCT03029689View on ClinicalTrials.gov

Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 28, 2017

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions

HIV

Interventions

DRUG

Raltegravir

Raltegravir 1200 mg (2 tablets x 600mg) once daily plus current ART during 48 weeks from randomization

DRUG

Placebo

Placebo (2 tablets of placebo) once daily plus current ART during 48 weeks from randomization.

DRUG

Current ART

3-drug antiretroviral treatment including PI/r/c or NNRTI

Trial Locations (1)

08916

Germans Trias i Pujol Hospital, Badalona

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

NCT03029689 - Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY | Biotech Hunter | Biotech Hunter